Gilead Sciences (NASDAQ:GILD) Rating Lowered to “Buy” at Wall Street Zen

Gilead Sciences (NASDAQ:GILD) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.

Other research analysts also recently issued reports about the company. Mizuho upped their price target on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Argus increased their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. TD Cowen boosted their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Royal Bank Of Canada raised their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. Finally, JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $131.54.

Gilead Sciences Stock Up 2.3%

GILD stock opened at $124.29 on Friday. The company has a market cap of $154.20 billion, a price-to-earnings ratio of 19.27, a P/E/G ratio of 0.67 and a beta of 0.32. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The business’s 50-day moving average is $122.35 and its two-hundred day moving average is $116.11. Gilead Sciences has a fifty-two week low of $88.57 and a fifty-two week high of $128.70.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the previous year, the company posted $2.02 EPS. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $126.54, for a total transaction of $1,265,400.00. Following the completion of the sale, the chief executive officer owned 571,203 shares of the company’s stock, valued at $72,280,027.62. The trade was a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the transaction, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This trade represents a 35.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 136,257 shares of company stock valued at $16,723,492 in the last ninety days. 0.27% of the stock is currently owned by company insiders.

Institutional Trading of Gilead Sciences

A number of hedge funds have recently bought and sold shares of the business. Sivik Global Healthcare LLC raised its holdings in shares of Gilead Sciences by 25.0% during the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $5,544,000 after buying an additional 10,000 shares in the last quarter. One Wealth Advisors LLC grew its position in Gilead Sciences by 34.8% during the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after acquiring an additional 2,364 shares during the last quarter. Invesco Ltd. grew its position in Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares during the last quarter. Jump Financial LLC purchased a new position in shares of Gilead Sciences during the second quarter worth approximately $6,988,000. Finally, Simplify Asset Management Inc. lifted its holdings in shares of Gilead Sciences by 148.6% in the 2nd quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock worth $5,864,000 after acquiring an additional 31,618 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.